RESUMEN
BACKGROUND: Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) asthma is characterized by chronic rhinosinusitis and intolerance of aspirin and other COX1 inhibitors. Clinical data point to a heterogeneity within the N-ERD phenotype. OBJECTIVE: Our aim was to investigate immune mediator profiles in the lower airways of patients with N-ERD. METHODS: Levels of cytokines (determined by using Luminex assay) and eicosanoids (determined by using mass spectrometry) were measured in bronchoalveolar lavage fluid (BALF) from patients with N-ERD (n = 22), patients with NSAID-tolerant asthma (n = 21), and control subjects (n = 11). mRNA expression in BALF cells was quantified by using TaqMan low-density arrays. RESULTS: Lower airway eosinophilia was more frequent in N-ERD (54.5%) than in NSAID-tolerant asthma (9.5% [P = .009]). The type-2 (T2) immune signature of BALF cells was more pronounced in the eosinophilic subphenotype of N-ERD. Similarly, BALF concentrations of periostin and CCL26 were significantly increased in eosinophilic N-ERD and correlated with T2 signature in BALF cells. Multiparameter analysis of BALF mediators of all patients with asthma revealed the presence of 2 immune endotypes: T2-like (with an elevated level of periostin in BALF) and non-T2/proinflammatory (with higher levels of matrix metalloproteinases and inflammatory cytokines). Patients with N-ERD were classified mostly as having the T2 endotype (68%). Changes in eicosanoid profile (eg, increased leukotriene E4 level) were limited to patients with N-ERD with airway eosinophilia. Blood eosinophilia appeared to be a useful predictor of airway T2 signature (area under the curve [AUC] = 0.83); however, surrogate biomarkers had moderate performance in distinguishing eosinophilic N-ERD (for blood eosinophils, AUC = 0.72; for periostin, AUC = 0.75). CONCLUSIONS: Lower airway immune profiles show considerable heterogeneity of N-ERD, with skewing toward T2 response and eosinophilic inflammation. Increased production of leukotriene E4 was restricted to a subgroup of patients with eosinophilia in the lower airway.
Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Asma/inmunología , Eosinofilia/inmunología , Rinitis/inmunología , Sinusitis/inmunología , Adulto , Anciano , Aspirina/efectos adversos , Biomarcadores , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Líquido del Lavado Bronquioalveolar/inmunología , Eosinófilos/inmunología , Femenino , Humanos , Inflamación/inmunología , Leucotrieno E4/inmunología , Masculino , Persona de Mediana Edad , Lavado Nasal (Proceso) , Neutrófilos/inmunologíaRESUMEN
BACKGROUND: The 3 cysteinyl leukotrienes (cysLTs), leukotriene (LT) C4 (LTC4), LTD4, and LTE4, have different biologic half-lives, cellular targets, and receptor specificities. CysLT2R binds LTC4 and LTD4in vitro with similar affinities, but it displays a marked selectivity for LTC4in vivo. LTC4, but not LTD4, strongly potentiates allergen-induced pulmonary eosinophilia in mice through a CysLT2R-mediated, platelet- and IL-33-dependent pathway. OBJECTIVE: We sought to determine whether LTD4 functionally antagonizes LTC4 signaling at CysLT2R. METHODS: We used 2 different in vivo models of CysLT2R-dependent immunopathology, as well as ex vivo activation of mouse and human platelets. RESULTS: LTC4-induced CD62P expression; HMGB1 release; and secretions of thromboxane A2, CXCL7, and IL-33 by mouse platelets were all were blocked by a selective CysLT2R antagonist and inhibited by LTD4. These effects did not depend on CysLT1R. Inhaled LTD4 blocked LTC4-mediated potentiation of ovalbumin-induced eosinophilic inflammation; recruitment of platelet-adherent eosinophils; and increases in IL-33, IL-4, IL-5, and IL-13 levels in lung tissue. In contrast, the effect of administration of LTE4, the preferred ligand for CysLT3R, was additive with LTC4. The administration of LTD4 to Ptges-/- mice, which display enhanced LTC4 synthesis similar to that in aspirin-exacerbated respiratory disease, completely blocked the physiologic response to subsequent lysine-aspirin inhalation challenges, as well as increases in levels of IL-33, type 2 cytokines, and biochemical markers of mast cell and platelet activation. CONCLUSION: The conversion of LTC4 to LTD4 may limit the duration and extent of potentially deleterious signaling through CysLT2R, and it may contribute to the therapeutic properties of desensitization to aspirin in aspirin-exacerbated respiratory disease.
Asunto(s)
Plaquetas/inmunología , Leucotrieno C4/inmunología , Leucotrieno D4/inmunología , Pulmón/inmunología , Activación Plaquetaria/inmunología , Animales , Asma/inmunología , Cisteína/inmunología , Citocinas/inmunología , Leucotrieno E4/inmunología , Leucotrienos/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Eosinofilia Pulmonar/inmunología , Receptores de Leucotrienos/inmunologíaRESUMEN
Patients with clonal mast cell activation syndromes (MCAS) including cutaneous and systemic mastocytosis (SM) may present with symptoms of mast cell activation, but in addition can have organ damage from the local effects of tissue infiltration by clonal mast cells. Patients with nonclonal MCAS may have chronic or episodic mast cell activation symptoms with an increase in serum tryptase and/or urinary metabolites of histamine, prostaglandin D2, and leukotrienes. Symptoms of MCAS and SM can be managed by blockade of mediator receptors (H1 and H2 antihistamines, leukotriene receptor blockade), inhibition of mediator synthesis (aspirin, zileuton), mediator release (sodium cromolyn), anti-IgE therapy, or a combination of these approaches. Acute episodes of mast cell activation require epinephrine, and prolonged episodes may be addressed with corticosteroids. Patients with clonal mast cell syndromes may need a reduction in the number of mast cells to prevent severe symptoms including anaphylaxis and/or progression to aggressive diseases.
Asunto(s)
Antialérgicos/uso terapéutico , Glucocorticoides/uso terapéutico , Antagonistas de los Receptores Histamínicos/uso terapéutico , Antagonistas de Leucotrieno/uso terapéutico , Mastocitosis/tratamiento farmacológico , Antiasmáticos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Aspirina/uso terapéutico , Cromolin Sódico/uso terapéutico , Manejo de la Enfermedad , Histamina/inmunología , Histamina/metabolismo , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Humanos , Hidroxiurea/análogos & derivados , Hidroxiurea/uso terapéutico , Interleucina-6/inmunología , Interleucina-6/metabolismo , Leucotrieno E4/inmunología , Leucotrieno E4/metabolismo , Mastocitosis/inmunología , Mastocitosis/metabolismo , Omalizumab/uso terapéutico , Prostaglandina D2/inmunología , Prostaglandina D2/metabolismo , Triptasas/inmunología , Triptasas/metabolismoRESUMEN
Measurement of urinary leukotriene E4 (uLTE4) is a sensitive and noninvasive method of assaying total body cysteinyl leukotriene (CysLT) production and changes in CysLT production. Recent studies have reported on novel LTE4 receptor interactions and genetic polymorphisms causing CysLT variability. The applications of uLTE4 as a biomarker continue to expand, including evaluation of environmental exposures, asthma severity risk, aspirin sensitivity, predicting atopy in preschool age children, obstructive sleep apnea, and predicting susceptibility to leukotriene receptor antagonists.
Asunto(s)
Asma/orina , Leucotrieno E4/orina , Asma/inmunología , Biomarcadores/orina , Humanos , Leucotrieno E4/inmunología , RiesgoRESUMEN
Human type-2 CD8+ T cells are a cell population with potentially important roles in allergic disease. We investigated this in the context of severe asthma with persistent airway eosinophilia-a phenotype associated with high exacerbation risk and responsiveness to type-2 cytokine-targeted therapies. In two independent cohorts we show that, in contrast to Th2 cells, type-2 cytokine-secreting CD8+CRTH2+ (Tc2) cells are enriched in blood and airways in severe eosinophilic asthma. Concentrations of prostaglandin D2 (PGD2) and cysteinyl leukotriene E4 (LTE4) are also increased in the airways of the same group of patients. In vitro PGD2 and LTE4 function synergistically to trigger Tc2 cell recruitment and activation in a TCR-independent manner. These lipids regulate diverse genes in Tc2 cells inducing type-2 cytokines and many other pro-inflammatory cytokines and chemokines, which could contribute to eosinophilia. These findings are consistent with an important innate-like role for human Tc2 cells in severe eosinophilic asthma and suggest a potential target for therapeutic intervention in this and other diseases.
Asunto(s)
Asma/tratamiento farmacológico , Linfocitos T CD8-positivos/efectos de los fármacos , Lípidos/farmacología , Eosinofilia Pulmonar/tratamiento farmacológico , Células A549 , Asma/inmunología , Linfocitos T CD8-positivos/inmunología , Línea Celular Tumoral , Quimiocinas/inmunología , Citocinas/inmunología , Humanos , Hipersensibilidad/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Leucotrieno E4/inmunología , Recuento de Linfocitos/métodos , Mastocitos/efectos de los fármacos , Mastocitos/inmunología , Prostaglandina D2/inmunología , Eosinofilia Pulmonar/inmunología , Células Th2/efectos de los fármacos , Células Th2/inmunologíaRESUMEN
BACKGROUND: Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal airways.Many therapies do not have immediate effects,even which have side-effects.However,the effects of Xingbi gel for the treatment of AR was investigated. OBJECTIVE: We investigated the effects of Xingbi gel on serum levels of leukotriene E4 (LTE4) and immunoglobulin E (IgE), as well as eosinophil counts in the nasal mucosa using a guinea pig model of allergic rhinitis (AR). METHODS: In addition to a healthy control group without AR, guinea pigs with AR were randomly divided into untreated AR control group, low-dose Xingbi gel (0.2483 g/mL) group, high-dose Xingbi gel (0.4966 g/mL) group, and budesonide group. RESULTS: Compared to the healthy controls, untreated AR guinea pigs had significantly higher ethology scores, serum LTE4 and IgE levels, and nasal mucosa eosinophil counts (p <0.01). Treatments with low-dose Xingbi gel, high-dose Xingbi gel, and budesonide significantly reduced the ethology scores, serum LTE4 and IgE levels, and nasal mucosa eosinophil counts as compared to untreated AR model guinea pigs (p <0.01). CONCLUSION: Xingbi gel alleviates AR in part through inhibiting LTE4 and IgE production and reducing eosinophilia in the nasal mucosa.
Asunto(s)
Antialérgicos/farmacología , Medicamentos Herbarios Chinos/farmacología , Eosinofilia/tratamiento farmacológico , Inmunoglobulina E/sangre , Leucotrieno E4/sangre , Mucosa Nasal/efectos de los fármacos , Rinitis Alérgica/tratamiento farmacológico , Administración Intranasal , Animales , Antialérgicos/administración & dosificación , Biomarcadores/sangre , Budesonida/farmacología , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/administración & dosificación , Eosinofilia/sangre , Eosinofilia/inmunología , Geles , Cobayas , Inmunoglobulina E/inmunología , Leucotrieno E4/inmunología , Masculino , Mucosa Nasal/inmunología , Mucosa Nasal/metabolismo , Rinitis Alérgica/sangre , Rinitis Alérgica/inmunologíaRESUMEN
Cysteinyl leukotriene (cysLT) overproduction is a hallmark of aspirin-exacerbated respiratory disease (AERD), but its mechanism is poorly understood. Because adherent platelets can convert the leukocyte-derived precursor leukotriene (LT)A(4) to LTC(4), the parent cysLT, through the terminal enzyme LTC(4) synthase, we investigated the contribution of platelet-dependent transcellular cysLT production in AERD. Nasal polyps from subjects with AERD contained many extravascular platelets that colocalized with leukocytes, and the percentages of circulating neutrophils, eosinophils, and monocytes with adherent platelets were markedly higher in the blood of subjects with AERD than in aspirin-tolerant controls. Platelet-adherent subsets of leukocytes had higher expression of several adhesion markers than did platelet nonadherent subsets. Adherent platelets contributed more than half of the total LTC(4) synthase activity of peripheral blood granulocytes, and they accounted for the higher level of LTC(4) generation by activated granulocytes from subjects with AERD compared with aspirin-tolerant controls. Urinary LTE(4) levels, a measure of systemic cysLT production, correlated strongly with percentages of circulating platelet-adherent granulocytes. Because platelet adherence to leukocytes allows for both firm adhesion to endothelial cells and augmented transcellular conversion of leukotrienes, a disturbance in platelet-leukocyte interactions may be partly responsible for the respiratory tissue inflammation and the overproduction of cysLTs that characterize AERD.
Asunto(s)
Aspirina/efectos adversos , Asma Inducida por Aspirina/inmunología , Plaquetas/inmunología , Cisteína/inmunología , Leucocitos/inmunología , Leucotrienos/inmunología , Pólipos Nasales/inducido químicamente , Adulto , Anciano , Araquidonato 5-Lipooxigenasa/inmunología , Araquidonato 5-Lipooxigenasa/metabolismo , Aspirina/inmunología , Plaquetas/efectos de los fármacos , Broncoconstricción/inmunología , Cisteína/metabolismo , Femenino , Granulocitos/efectos de los fármacos , Granulocitos/inmunología , Humanos , Integrinas/inmunología , Leucotrieno E4/inmunología , Leucotrienos/metabolismo , Masculino , Persona de Mediana Edad , Pólipos Nasales/inmunología , Inhibidores de Agregación Plaquetaria/efectos adversos , Inhibidores de Agregación Plaquetaria/inmunología , Adulto JovenRESUMEN
BACKGROUND: Distinct receptors likely exist for leukotriene (LT)E(4), a potent mediator of airway inflammation. Purinergic receptor P2Y12 is needed for LTE(4)-induced airways inflammation, and P2Y12 antagonism attenuates house dust mite-induced pulmonary eosinophilia in mice. Although experimental data support a role for P2Y12 in airway inflammation, its role in human asthma has never been studied. OBJECTIVE: To test for association between variants in the P2Y12 gene (P2RY12) and lung function in human subjects with asthma, and to examine for gene-by-environment interaction with house dust mite exposure. METHODS: Nineteen single nucleotide polymorphisms (SNPs) in P2RY12 were genotyped in 422 children with asthma and their parents (n = 1266). Using family based methods, we tested for associations between these SNPs and five lung function measures. We performed haplotype association analyses and tested for gene-by-environment interactions using house dust mite exposure. We used the false discovery rate to account for multiple comparisons. RESULTS: Five SNPs in P2RY12 were associated with multiple lung function measures (P-values 0.0060.025). Haplotypes in P2RY12 were also associated with lung function (P-values 0.00550.046). House dust mite exposure modulated associations between P2RY12 and lung function, with minor allele homozygotes exposed to house dust mite demonstrating worse lung function than those unexposed (significant interaction P-values 0.00280.040). CONCLUSIONS AND CLINICAL RELEVANCE: The P2RY12 variants were associated with lung function in a large family-based asthma cohort. House dust mite exposure caused significant gene-by-environment effects. Our findings add the first human evidence to experimental data supporting a role for P2Y12 in lung function. P2Y12 could represent a novel target for asthma treatment.
Asunto(s)
Asma/genética , Interacción Gen-Ambiente , Polimorfismo de Nucleótido Simple , Pyroglyphidae , Receptores Purinérgicos P2Y12/genética , Animales , Asma/inmunología , Asma/fisiopatología , Niño , Estudios de Cohortes , Femenino , Humanos , Leucotrieno E4/inmunología , Pulmón/inmunología , Pulmón/fisiopatología , Masculino , Ratones , Eosinofilia Pulmonar/genética , Eosinofilia Pulmonar/inmunología , Eosinofilia Pulmonar/fisiopatología , Receptores Purinérgicos P2Y12/inmunología , Pruebas de Función RespiratoriaRESUMEN
Leukotriene (LT) E(4) mediates many of the principal features of bronchial asthma, such as bronchial constriction, hyperresponsiveness, eosinophilia, and increased vascular permeability. Furthermore, it is the most stable of the cysteinyl leukotrienes (CysLTs) and can be active at the site of release for a prolonged time after its synthesis. There might be several reasons why LTE(4) has been forgotten. LTE(4) demonstrated low affinity for CysLT(1) and CysLT(2) receptors in equilibrium competition assays. It was less potent than other CysLTs in functional assays, such as calcium flux, in cells transfected with CysLT(1) and CysLT(2). The introduction of CysLT(1) antagonists into clinical practice diverted interest into CysLT(1)-related mechanisms, which were mediated mainly by LTD(4). However, experiments with animal models and human studies have revealed that LTE(4) has unique characteristics that cannot be explained by the current knowledge of CysLT(1) and CysLT(2). These activities include its potency relative to other CysLTs to increase airway responsiveness to histamine, to enhance eosinophilic recruitment, and to increase vascular permeability. Asthmatic airways also demonstrate marked in vivo relative hyperresponsiveness to LTE(4), especially in patients with aspirin-sensitive respiratory disease. This has stimulated a search for additional LT receptors that would respond preferentially to LTE(4) stimulation.
Asunto(s)
Asma/inmunología , Hiperreactividad Bronquial/inmunología , Hipersensibilidad a las Drogas/inmunología , Leucotrieno E4/inmunología , Animales , Aspirina/efectos adversos , Asma/tratamiento farmacológico , Hiperreactividad Bronquial/tratamiento farmacológico , Hipersensibilidad a las Drogas/tratamiento farmacológico , Histamina , Humanos , Leucotrieno C4/inmunología , Leucotrieno D4/inmunología , Cloruro de Metacolina , Receptores de Leucotrienos/inmunología , Piel/efectos de los fármacos , Piel/inmunología , Piel/patologíaRESUMEN
Cysteinyl leukotrienes (CysLTs: leukotrienes C(4), D(4), and E(4)) have long been implicated in the pathogenesis of asthma and several allergic diseases. LTE(4) has been identified as a major metabolite of LTC(4), and urinary LTE(4) (U-LTE(4)) is considered as the most reliable analytic parameter for monitoring the endogenous synthesis of CysLTs. From recent studies on the U-LTE(4) associated with adult stable asthma we identified four factors for hyperleukotrieneuria, namely, aspirin intolerance, eosinophilic nasal polyposis (ENP), vasculitis, and severe asthma. In ENP, there is prominent infiltration of eosinophils in the sinus and polyp tissues, which is linked to adult asthma and aspirin sensitivity, and ENP is the most important factor for the overproduction of CysLTs in asthmatics. We also demonstrated that anaphylaxis and eosinophilic pneumonia (EP) are associated with a marked increase in the U-LTE(4) concentration. Under these disease conditions, U-LTE(4) may be one of the candidate biomarkers. Moreover, the changes in U-LTE(4) concentrations may provide valuable information concerning therapeutic targets.
Asunto(s)
Asma/inmunología , Hipersensibilidad a las Drogas/inmunología , Leucotrieno E4/metabolismo , Pólipos Nasales/inmunología , Vasculitis/inmunología , Aspirina/inmunología , Asma/complicaciones , Asma/patología , Asma/fisiopatología , Biomarcadores/orina , Movimiento Celular/inmunología , Hipersensibilidad a las Drogas/complicaciones , Hipersensibilidad a las Drogas/patología , Hipersensibilidad a las Drogas/fisiopatología , Eosinófilos/inmunología , Eosinófilos/metabolismo , Eosinófilos/patología , Regulación de la Expresión Génica/inmunología , Inflamación , Leucotrieno E4/inmunología , Leucotrieno E4/orina , Pólipos Nasales/complicaciones , Pólipos Nasales/patología , Pólipos Nasales/fisiopatología , Factores de Riesgo , Vasculitis/complicaciones , Vasculitis/patología , Vasculitis/fisiopatologíaRESUMEN
Leukotrienes are biologically active metabolites derived from arachidonic acid playing an important role in inflammatory responses. There are two main groups of leukotrienes: dihydroxyleukotrienes (LTB4) and cysteinyl-leukotrienes (LTC4, LTD4, LTE4). By activating specific G-protein coupled receptors, leukotrienes take part in immune responses, like activation and chemotaxis of leukocytes. Several studies have shown that leukotrienes may play a significant role in pathomechanisms of inflammatory diseases of human airways, skin, digestive tract and heart.
Asunto(s)
Mediadores de Inflamación/inmunología , Leucotrienos/inmunología , Quimiotaxis/inmunología , Humanos , Mediadores de Inflamación/metabolismo , Leucotrieno B4/inmunología , Leucotrieno C4/inmunología , Leucotrieno D4/inmunología , Leucotrieno E4/inmunología , Leucotrienos/metabolismo , Activación de Linfocitos/inmunologíaRESUMEN
Urinary leukotriene E4 (LTE4) has been used as an index of total leukotriene synthesis. A wide variety of methods have been applied to measure LTE4 which has made direct comparison of urinary levels reported by different laboratories difficult. A new peptidoleukotriene immunoaffinity resin was utilized for urinary LTE4 purification in a method that is easy and inexpensive, utilizing commercially available reagents. This method is described and compared to other methods. LTE4 (50-250 pg/mL) added to a urine extract was quantitatively recovered using the immunoaffinity resin. Similarly, LTE4 (50-400 pg/mL) added to urine was recovered between 63 and 76%. The coefficient of variation of samples purified and quantified on the same or on different days ranged from 8-10%. There was a strong correlation (r2 = 0.95) between LTE4 concentrations determined after immunofiltration and immunoaffinity purification. Although there was a good correlation between urinary LTE4 levels measured without purification compared to after immunoaffinity purification, the high y-intercept of 179 indicates the presence of interfering substances in unpurified urine. Urinary LTE4 in normal healthy adults was 80 +/- 7 pg/mg creatinine, similar to that previously reported following HPLC or immunofiltration purification. Urinary LTE4 was also measured in healthy children (age 3-12) and found to be 103 +/- 9.
Asunto(s)
Cromatografía de Afinidad/métodos , Leucotrieno E4/inmunología , Leucotrieno E4/orina , Adulto , Anticuerpos Monoclonales/inmunología , Niño , Preescolar , Hemocianinas/inmunología , Humanos , Técnicas para Inmunoenzimas , Inmunoadsorbentes , Persona de Mediana Edad , Reproducibilidad de los ResultadosRESUMEN
Leukotriene E4 (LTE4) is a major leukotriene metabolite in urine. Urinary LTE4 concentration is often utilized as an index of total leukotriene synthesis. A novel method employing immunofiltration for the purification of urinary LTE4 was developed. This immunofiltration method is based upon the addition of excess anti-LTE4 antibody to urine which binds LTE4. Separation of bound LTE4 (high M(r)) from high levels of unbound contaminants (low M(r)) is then accomplished by filtration through a 10,000 M(r) cut-off filter. The LTE4-antibody complex is separated by precipitation of the antibody with methanol which is subsequently removed by centrifugation. Following evaporation of the methanol, enzyme immunoassay is utilized for quantitation. This methodology was validated by determining the recovery of tritiated and unlabeled LTE4 added to urine and buffer and by comparison of results obtained with urine samples measured after HPLC purification (correlation r2 = 0.72). Reproducibility of the assay was assessed by analyzing the same sample on two different days (standard deviation of 18%). The mean urinary LTE4 levels in healthy subjects and asthmatics measured utilizing this method were found to be identical to levels determined by HPLC/immunoassay. The ease and accuracy of this assay make it amenable for the analysis of large numbers of samples.
Asunto(s)
Filtración/métodos , Técnicas para Inmunoenzimas , Leucotrieno E4/orina , Anticuerpos Monoclonales , Cromatografía Líquida de Alta Presión/métodos , Humanos , Leucotrieno E4/inmunología , Reproducibilidad de los ResultadosRESUMEN
The objective of this study was to define the participation of cysteinyl leukotrienes (LTs) or thromboxane A2 in the pathogenesis of aspirin-sensitive asthma (ASA). Leukotriene E4 (LTE4) and 11-dehydrothromboxane B2 (11DTXB2) values in spot urine were measured in 22 asthmatics with a history of aspirin sensitivity and in 17 without such a history (non-aspirin-sensitive asthma [NASA]) in the outpatient clinic. The urinary LTE4 value was significantly higher in ASA patients than in NASA (340 +/- 47 vs 65 +/- 15 pg/mg.cr, P < 0.001), but there was no significant difference in urinary 11DTXB2 between the two groups (891 +/- 77 vs 657 +/- 90 pg/mg.cr). A high value of LTE4 was not associated with type of asthma, severity of disease, oral prednisolone treatment, sex, or age. A higher value of 11DTXB2 was observed in the atopic type than the nonatopic type in ASA (1086 +/- 111 vs 697 +/- 147 pg/mg.cr, P < 0.05). No correlation was observed between urinary LTE4 and 11DTXB2 in either ASA or NASA. In conclusion, LTs may play an important role in the pathogenesis of ASA, and TXA2 in the pathogenesis of the atopic type in ASA.
Asunto(s)
Aspirina/efectos adversos , Asma/etiología , Asma/orina , Hipersensibilidad a las Drogas/complicaciones , Leucotrieno E4/orina , Tromboxano B2/análogos & derivados , Estudios de Casos y Controles , Hipersensibilidad a las Drogas/inmunología , Femenino , Humanos , Leucotrieno E4/inmunología , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Tromboxano B2/inmunología , Tromboxano B2/orinaRESUMEN
To monitor endogenous production of cysteinyl-containing leukotrienes, the end-metabolite leukotriene E4 (LTE4) was analysed in urine. Results obtained with a sensitive enzyme immunoassay (EIA), performed on crude urine samples correlated well with data obtained from a previously reported radioimmunoassay. Enzyme immunoassay analysis of unextracted urine was justified by an excellent agreement between analyses in crude samples and measurements achieved after purification on solid phase extraction followed by separation on reversed-phase high performance liquid chromatography. Moreover, LTE4 was stable in urine samples stored at -20 degrees C, for months without the addition of preservatives. The stability of LTE4 in urine was not improved by addition of the antioxidant 4-hydroxy-TEMPO and pH adjustment to 9. As assessed by EIA analysis in crude urine samples, baseline values for urinary leukotriene E4 were not significantly different between atopic asthmatic subjects and non-asthmatic individuals, and there was no diurnal variation in urinary excretion of LTE4 in healthy subjects. However, we confirmed earlier data on significantly higher basal levels of urinary LTE4 in aspirin-intolerant asthmatics. In addition, a post-challenge increase in urinary LTE4 levels was detected in association with allergen-induced airway obstruction in atopic asthmatics. The per cent increase in urinary LTE4 was similar, irrespective of whether the samples were purified or not prior to EIA. Thus, combined with random validation by high performance liquid chromatography, the strategy of direct EIA of serially diluted urine samples was found to be a good index of in vivo production of leukotrienes. This was further reinforced by the demonstration that pretreatment with the leukotriene biosynthesis inhibitor Bay x 1005 inhibited the post allergen-challenge increase in urinary LTE4, as shown both with unpurified and purified samples.